BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22369373)

  • 21. BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry.
    Loo E; Khalili P; Beuhler K; Siddiqi I; Vasef MA
    Appl Immunohistochem Mol Morphol; 2018; 26(10):709-713. PubMed ID: 29271794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C; Obiols G
    Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
    Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
    Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutations in papillary carcinomas of the thyroid.
    Fukushima T; Suzuki S; Mashiko M; Ohtake T; Endo Y; Takebayashi Y; Sekikawa K; Hagiwara K; Takenoshita S
    Oncogene; 2003 Sep; 22(41):6455-7. PubMed ID: 14508525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
    Sclafani F; Gullo G; Sheahan K; Crown J
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of ERK3/MAPK6 expression by BRAF.
    Hoeflich KP; Eby MT; Forrest WF; Gray DC; Tien JY; Stern HM; Murray LJ; Davis DP; Modrusan Z; Seshagiri S
    Int J Oncol; 2006 Oct; 29(4):839-49. PubMed ID: 16964379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
    Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
    Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF mutation in thyroid cancer.
    Xing M
    Endocr Relat Cancer; 2005 Jun; 12(2):245-62. PubMed ID: 15947100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequencing analysis of BRAF mutations in human cancers.
    Wooster R; Futreal AP; Stratton MR
    Methods Enzymol; 2006; 407():218-24. PubMed ID: 16757326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF--a new player in hematological neoplasms.
    Machnicki MM; Stoklosa T
    Blood Cells Mol Dis; 2014; 53(1-2):77-83. PubMed ID: 24495477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome.
    Champion KJ; Bunag C; Estep AL; Jones JR; Bolt CH; Rogers RC; Rauen KA; Everman DB
    Clin Genet; 2011 May; 79(5):468-74. PubMed ID: 20735442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological relevance of BRAF mutations in human cancer.
    Pakneshan S; Salajegheh A; Smith RA; Lam AK
    Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [BRAF mutation testing for the choice of melanoma treatment].
    Imianitov EN
    Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR.
    Kristensen T; Clemmensen O; Hoejberg L
    J Mol Diagn; 2013 May; 15(3):355-61. PubMed ID: 23499336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.